Vivoryon Therapeutics N.V. (LON:0R3M)

Market Cap	33.63M -21.1%
Revenue (ttm)	n/a
Net Income	-10.70M
EPS	-0.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76
Average Volume	889
Open	1.376
Previous Close	1.320
Day's Range	1.322 - 1.376
52-Week Range	1.250 - 1.980
Beta	1.52
RSI	41.74
Earnings Date	Apr 24, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1997
• Employees: 14
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R3M

Financial Performance

Financial numbers in EUR